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American Academy of Allergy, Asthma & Immunology Work Group Report: 
Allergy diagnosis in clinical practice  
To the Editor:  
 
At the request of the American Academy of Allergy, Asthma & Immunology (AAAAI) 
Board, the Practice Diagnostics and Therapeutics Committee orchestrated the development of 
a paper entitled ‘‘AAAAI Work Group Report: Allergy Diagnosis in Clinical Practice’’ to 
communicate the optimal methods for the diagnosis of allergic disorders to the entire medical 
community. This letter represents the opinion of the work group, and it summarizes the key 
points of that report, which has been posted on the AAAAI Web site.
1  
 
The diagnostic algorithm for allergic disorders starts with a chief complaint and 
comprehensive history, which is often the most important and definitive diagnostic tool 
available to the clinician. It is important to determine the onset, frequency, severity, pattern, 
triggers, and success or failure of prior treatment for each allergic symptom. The presence of 
related comorbid allergic problems must also be determined in the review of systems. It is 
important to assess the effect of the allergic symptoms on the patient’s quality of life, eg, days 
missed from work or school and emergency room visits. The allergist will review the family 
history of allergic and medical problems, an environmental survey, occupational exposure, 
and social history. Physical examination should be conducted with emphasis on the organs 
affected by the allergic complaints. Diagnostic procedures may be required, eg, spirometry for 
asthma or determination of immediate-type hypersensitivity to identify allergenic triggers for 
of the patient’s symptoms. Additional office-based diagnostic procedures such as 
rhinolaryngoscopy, tympanometry, oral provocation testing for foods or medications, and 
patch testing for delayed-type hypersensitivity may be used for certain evaluations.  
 
Skin testing, prick/puncture and/or intracutaneous, is used to help confirm the clinical 
history in the evaluation of suspected inhalant, food, insect, and drug allergy and remains the 
preferred technique for most allergists. These in vivo procedures have demonstrated 
reliability, speed, cost effectiveness, and ease of performance. They are appropriate for any 
age patient and allow direct observation of a biologic response in the patient. Specific allergen 
tests along with histamine (positive control) and human albumin saline (negative control) are 
applied to the back and/or arm of the patient. The wheal and flare responses are recorded in 
mm (diameter or area) at 15-20 minutes following application for prick/puncture and 10-15 
minutes for intracutaneous tests.
2 
Although a 0 to 14 scoring scale is often used,
3 
it should not 
replace the measurement of induration and erythema.
2 
Although a 3mm increase in wheal size 
over the negative control is generally considered a positive prick/puncture test result, there is 
much less agreement on what constitutes a significantly positive intradermal skin test result.
2 
In general, reactivity by prick/puncture testing is the most specific, whereas intradermal 
testing is more sensitive.
2 
The diagnostic accuracy of intracutaneous tests is greater than 
prick/puncture when testing with insect venom or certain drugs,
2 
but appropriate interpretation 
in the evaluation of inhalant allergy remains controversial despite widespread use. The 
diagnostic validity of the prick/puncture tests has been confirmed by natural exposure and 
organ allergy challenge. The reliability of both types of skin tests depends upon the skill of the 
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tester and the potency and stability of the test reagents. Variability of skin reactivity in an 
individual patient may relate to such factors as age (less reactivity in infants and the elderly), 
skin color, time of day, timing in relation to pollen season (eg, increased reactivity following 
pollen season),4 and placement on the body (eg, the back is more reactive than the forearm).2 
Skin testing will, in general, start with prick/ puncture testing, the safer of the skin testing 
techniques. It may be followed by intracutaneous tests for inhalant allergens only when 
prick/puncture skin test results are negative and increased sensitivity is the main objective, eg, 
due to a convincing history of exposure and symptoms, lower skin prick test reactivity, or low 
potency allergenic extracts.
2 
In a recent survey of US allergists, 85.2% performed intradermal 
skin tests for inhalant allergens.
3 
Although less allergen is introduced for the prick/puncture 
tests, life-threatening systemic reactions are rarely caused by either method of testing. 
However, the clinician must have experience in treating adverse reactions and appropriate 
resources available for treating anaphylaxis.
5 
 
There are several important precautions to take when planning allergy skin testing. 
Antihistamines should usually be discontinued for 3-10 days depending upon the agent.
2 
Tricyclic antidepressants and some tranquilizers may need to be discontinued for up to a few 
weeks. As patients taking a b-blocker may be more difficult to treat in the event of a systemic 
reaction, current allergy diagnostic and immunotherapy practice parameters recommend that a 
cautious attitude toward these agents should be maintained, avoiding their concurrent use 
during allergy testing and immunotherapy when possible.
2,6 
Although the use of an 
angiotensin-converting enzyme inhibitor
7 
and monoamine oxidase inhibitors in patients 
undergoing skin testing has been questioned based upon potentially increased risk of more 
severe anaphylaxis in other situations, no increased risks have been demonstrated for allergy-
directed diagnosis or treatment in patients being treated with these agents.
2,7  
 
Newer in vitro specific IgE assays such as the ImmunoCAP (Pharmacia Diagnostics, 
Uppsala, Sweden) and Immulite (Diagnostics Product Corporation, Los Angeles, Calif) 
replace the older RAST. With these assays, the allergist has an alternative method for 
screening allergy testing. The test can detect sensitization as evidenced by the presence of IgE 
antibody specific for a given allergen. However, as in skin testing, an important role for the 
clinician is interpreting what level of IgE antibody is clinically significant. When interpreting 
the significance of the quantitative level, the total IgE must be taken into consideration, as, for 
example, an extremely high total level can be associated with many ‘‘positive’’ results that are 
not clinically relevant.
2 
Allergen-specific IgE antibody measurements from different 
laboratories may not be equivalent. Ideally the commercial laboratory is Clinical Laboratory 
Improvement Act of 1988 certified, uses an allergosorbent that has been Food and Drug 
Administration–cleared, is able to provide an external proficiency survey demonstrating 
reliability and reproducibility, and uses an IgE antibody assay that reports results in 
quantitative kUA/L units.
2 
Although a detailed review of the laboratory by the clinician prior 
to ordering in vitro testing can be important in selecting the preferred laboratory and method 
for specific IgE testing, this is not always possible because laboratory selection may be 
dictated by the third-party payor.  
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Advantages of in vitro testing include elimination of any systemic reaction risk (eg, severe 
food, drug, or insect sting allergy), continuation of the patient’s current medications, and use 
in patients with severe eczema or dermographism. It also provides an option for nonallergists 
to use a multiple-allergen screening test, eg, testing up to 15 aeroallergens with 1 test, which 
has been shown to have a high negative predictive value compared with prick/ puncture 
testing.
2 
Disadvantages include a delay in obtaining results, the lack of visible ‘‘proof’’ for the 
patient, and the possibility of false-negative results not confirmed by a second technique as 
occurs when prick/puncture testing is followed by selected intracutaneous tests. Assessment of 
food specific IgE levels may be used to eliminate the need for oral food challenges based on 
certain cut-off levels and predictive values.
8 
However, for insect venom and drugs, it is 
advised to use a combination of in vitro specific IgE and in vivo percutaneous and intradermal 
skin testing.
2  
 
The number of specific IgE tests performed in individual patients is guided by the patient’s 
age (eg, more foods and less aeroallergens in the young child), seasonal versus nonseasonal 
symptoms, botanical cross-sensitivity, occupation, anaphylaxis to foods, drugs, or venom, and 
frequent travel to other floristic zones.
2 
The experienced clinician recognizes that at times, 
negative results are as helpful as positive results in patient management. In interpreting 
specific IgE tests, a positive test result indicates sensitization and does not necessarily mean 
that symptoms are due to an IgE-mediated allergy.  
 
Organ challenge, with allergen applied topically, by inhalation, or ingestion, to the skin or 
the mucosa of the conjunctivae, nares, bronchi, or gastrointestinal tract is often considered the 
gold standard when there is poor correlation of specific IgE measures with clinical symptoms.
2 
Experience and appropriate precautions with these  methods are required for proper testing 
and interpretation. Although organ challenges are often considered a research tool, a 
commonly used in-office procedure is titrated food challenge testing, preferably in a double-
blind or a single-blind manner.
9  
 
It is ultimately up to the experienced and skilled clinician to combine the elements of 
medical history, physical findings, and diagnostic allergy testing to reach a correct diagnosis 
and to formulate an appropriate treatment plan.  
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